Physician profile
Aly Cohen
NPI 1346294188
$4,196.48
in general payments reported to CMS, 2019-2025
21 companies · $513 in 2025
The $513 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $467 · 2021: $623 · 2022: $545 · 2023: $513 · 2024: $595 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319 · Education: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.11 |
| Education | $301.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,218.98 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $565.46 | 2019-2025 | Tremfya |
| Ucb, INC. | $559.36 | 2019-2025 | Cimzia, Bimzelx |
| Genentech USA, INC. | $416.18 | 2019-2020 | |
| Pfizer INC. | $377.26 | 2019-2024 | |
| Amgen INC. | $193.71 | 2019-2023 | Enbrel, Tavneos |
| Lilly USA, LLC | $149.13 | 2019-2021 | |
| Genzyme Corporation | $108.44 | 2019-2021 | |
| Glaxosmithkline, LLC. | $108.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $104.82 | 2019-2022 | |
| Cardinal Health 110 LLC | $100.00 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $57.61 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.91 | 2019-2021 | |
| Horizon Therapeutics Plc | $40.06 | 2020-2023 | Krystexxa |
| Collegium Pharmaceutical, INC. | $30.87 | 2022-2025 | Belbuca |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.84 | 2021-2024 | Saphnelo |
| Organon LLC | $28.72 | 2021-2023 | Renflexis, Hadlima |
| Kowa Pharmaceuticals America, INC. | $14.35 | 2022 | |
| Celgene Corporation | $14.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2024 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $13.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aly Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.